Globus Medical GMED Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Globus Medical in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Globus Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Globus Medical's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Globus Medical's cash & equivalents?
- Globus Medical (GMED) reported cash & equivalents of $560.95M in Q1 2026.
- How has Globus Medical's cash & equivalents changed year-over-year?
- Globus Medical's cash & equivalents increased by 21.6% year-over-year, from $461.27M to $560.95M.
- What is the long-term trend for Globus Medical's cash & equivalents?
- Over 5 years (2020 to 2025), Globus Medical's cash & equivalents has grown at a 17.1% compound annual growth rate (CAGR), from $239.4M to $526.16M.
- What does cash & equivalents mean?
- The total value of cash and highly liquid investments that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or operational cash burn.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in medical devices typically maintain sufficient cash to support R&D and M&A activity.